A Study of Metyrapone and Oxazepam Combination Product (EMB-001) and Cocaine
A Phase 1b, Randomized, Double-Blinded, Multiple-Dose, Placebo Controlled, Crossover Study To Evaluate The Safety, Tolerability And Pharmacokinetic Effects Of A Metyrapone And Oxazepam Combination (EMB-001) When Co-Administered With Cocaine
Sponsor: Embera NeuroTherapeutics, Inc.
Listed as NCT02856854, this PHASE1 trial focuses on Cocaine Use Disorder and remains completed. Sponsored by Embera NeuroTherapeutics, Inc., it has been updated 7 times since 2016, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1
-
Aug 2017 — Jun 2018 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
▶ Show 2 earlier versions
-
Feb 2017 — Aug 2017 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1
First recorded
Jul 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Embera NeuroTherapeutics, Inc.
- National Institute on Drug Abuse (NIDA)
For direct contact, visit the study record on ClinicalTrials.gov .